APVAC1 vaccine / BioNTech, Immatics - LARVOL DELTA

Targeting glioblastoma stem cells with an HLA-A*02-restricted TCR specific to cancer-associated antigen, PTPRZ1 (CIMT 2024) - "Here, we leveraged vaccine-induced T cell responses from the GAPVAC trial, where GB patients were immunized with a pool of peptides covering unmutated GB-associated antigens (APVAC1), including protein tyrosine phosphatase type Z1 (PTPRZ1)...Encouraged by these findings, we are preparing a phase 1 clinical trial, Intraventricular T cell receptor transgenic T cell therapy to treat glioblastoma (INVENT4GB), to assess the feasibility and safety of i.v. and i.cv. PTPRZ1-TCR-T cell therapy in patients with recurrent GB."

IO biomarker • Brain Cancer • CNS Tumor • Glioblastoma • Hematological Malignancies • Oncology • Solid Tumor • CD4 • CD8 • HLA-A • PTPRZ1

Targeting glioblastoma stem cells with an HLA-A*02-restricted TCR specific to cancer-associated antigen, PTPRZ1 (CIMT 2024) - "Here, we leveraged vaccine-induced T cell responses from the GAPVAC trial, where GB patients were immunized with a pool of peptides covering unmutated GB-associated antigens (APVAC1), including protein tyrosine phosphatase type Z1 (PTPRZ1)...Encouraged by these findings, we are preparing a phase 1 clinical trial, Intraventricular T cell receptor transgenic T cell therapy to treat glioblastoma (INVENT4GB), to assess the feasibility and safety of i.v. and i.cv. PTPRZ1-TCR-T cell therapy in patients with recurrent GB."

IO biomarker • Brain Cancer • CNS Tumor • Glioblastoma • Hematological Malignancies • Oncology • Solid Tumor • CD4 • CD8 • HLA-A • PTPRZ1

Efficacy and Safety of Actively Personalized Neoantigen Vaccination in the Management of Newly Diagnosed Glioblastoma: A Systematic Review. (PubMed, Int J Gen Med) - "The GAPVAC-101 trial reported 50% APVAC1-induced and 84.7% APVAC2-induced immunogenicity with CD8+ and CD4+ T cell responses in 92% (12/13) and 80% (8/10) immune responders, respectively...Dexamethasone use had limited immunogenicity in a trial by Keskin et al (6/8)...Actively personalized vaccines aimed at unmutated peptides and neoantigens for patients with GBM are safe and highly immunogenic, particularly when administered in combination. Larger studies are warranted to investigate the role."

Clinical • Journal • Review • Tumor-specific neoantigens • Brain Cancer • Glioblastoma • Oncology • Solid Tumor • CD4 • CD8